Abstract
A double-blind trial of prednisolone in patients with rheumatoid arthritis using doses of zero, 3 mg and 5 mg is reported. Patients on a dose of 3 mg derived little sustained benefit but subjects on the higher dose showed some improvement which did not last more than two years. Mild suppression of the hypothalamo-pituitary-adrenal axis occurred in both steroid-treated groups.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
MeSH terms
-
Adrenal Glands / drug effects*
-
Adult
-
Aged
-
Arthritis, Rheumatoid / drug therapy*
-
Clinical Trials as Topic
-
Dose-Response Relationship, Drug
-
Drug Evaluation
-
Female
-
Humans
-
Hypothalamus / drug effects*
-
Male
-
Middle Aged
-
Movement
-
Muscle Contraction
-
Pituitary Gland / drug effects*
-
Placebos
-
Prednisolone / adverse effects
-
Prednisolone / therapeutic use*
-
Remission, Spontaneous
-
Time Factors